Cell Targeting, Inc Asset Purchase (Tables) (Cell Targeting, Inc. [Member])

12 Months Ended

Dec. 31, 2013

Cell Targeting, Inc. [Member]

Business Acquisition [Line Items]

Allocation of purchase price for the acquisition

The total purchase price of $2,550,000 is being allocated as indicated as follows:

Components of the purchase price:
BioTime common shares	$	2,300,000
Cash		250,000
Total purchase price	$	2,550,000
Preliminary allocation of purchase price:
Assets acquired and liabilities assumed:
Cash	$	3,150
Other current assets		2,443
Due from sellers		593,353
Intangible assets		2,419,287
Current liabilities		(468,233	)
Net assets acquired	$	2,550,000